Pyoderma gangrenosum (PG) is an orphan disease. While research on such disorders is based on only few randomized multicenter as well as retrospective studies, most of the data comes from case series of small patient groups. Apart from topical and intralesional therapeutic options for early stages and mild disease courses, treatment predominantly involves systemic therapeutic agents. Besides systemic corticosteroids and cyclosporine A (CsA), options also include intravenous immunoglobulins (IVIG) and biologics such as the TNF α inhibitors infliximab, adalimumab, and etanercept; the interleukin (IL) 12/23 antibody ustekinumab; the IL-1 receptor antagonist anakinra; and the IL-1 β antibody canakinumab. The best evidence-based study data is available for CsA, prednisolone, and infliximab; the latter especially in patients with concomitant ulcerative colitis or Crohn's disease. A response to IVIG and canakinumab has been reported in smaller case series. First described by Brocq almost 100 years ago, it was soon recognized that PG did in fact require treatment. To this day, however, such treatment remains a clinical challenge. Despite the severe -albeit rare -clinical picture, improvement in therapeutic options may be expected in the future, primarily due to further clinical studies -especially with a greater number of patients, a better understanding of the etiopathogenesis, as well as the use of modern targeted therapies with higher efficacy and a lower rate of side effects than conventional immunosuppressants such as prednisolone and CsA.
Introduction
A rare neutrophilic dermatosis marked by recurrent fl are-ups, pyoderma gangrenosum (PG) is clinically characterized by painful, sterile, necrotizing ulcerations, which may occur as solitary lesions or in a disseminated manner. Predilection sites include the pretibial region as well as peristomal sites. With an incidence of 0.3-1.0/100,000 [ 1 ] , PG is an orphan disease. While research on such disorders is based on only very few randomized trials as well as some multicenter and retrospective studies, most of the data comes from multiple case series and recent genetic studies of small patient groups.
Important diagnostic clues include disease persistence or progression despite modern wound therapy as well as a response to immunosuppressive therapy associated with pain reduction [2] [3] [4] [5] . While infl ammatory bowel disease (IBD; ulcerative colitis, Crohn's disease) is among the most common comorbidities (6-36 %), PG makes up approximately 1-3 % of extraintestinal manifestations in IBD patients [ 6, 7 ] . Gene variants associated with IBD and rheumatoid arthritis have been mapped to chromosome 15 [ 8 ] .
Overall, there is evidence for PG to be considered among the group of autoinfl ammatory diseases. Given that these disorders are characterized by a dysregulation of the innate immune system, this has opened up new therapeutic approaches, such as the use of certain biologics (TNF α inhibitors, IL-1 β antibodies). Experimental studies have demonstrated Th1-weighted overexpression of interleukin (IL)-1 β , IL-1 α , tumor necrosis factor-α (TNF α ), IL-6, IL-8, IL-17, IL-23, IL-36 α , CXCL1/2/3, RANTES, and Fas ligands [9] [10] [11] .
Treatment options
A distinction is made between topical, intralesional, and systemic therapies. In PG, topical or intralesional therapy frequently leads to only insuffi cient control of disease activity, thus necessitating the additional use of systemic therapeutic agents such as corticosteroids, other immunosuppressants, or biologics. One problem that complicates the selection of therapeutic options is the lack of a uniform treatment standard, due to the rarity of the disease and the lack of robust evidence provided by randomized double-blind studies.
Using a standardized questionnaire, a German survey on the treatment of PG among wound experts revealed that 11 % of PG patients exclusively received topical treatment; 22.7 %, only systemic treatment; and 66.2 %, combined topical and systemic therapy [ 12 ] . Preferred topical treatment options were class III and IV corticosteroids (78 % and 88 %, respectively). Employed systemic agents included corticosteroids (100 %), CsA (74 %), TNF α inhibitors (24 %), azathioprine (20 %), mycophenolate mofetil (20 %), dapsone (16 %), intravenous immunoglobulins (IVIG) (14 %), methotrexate (6 %), cyclophosphamide (4 %), tacrolimus (4 %), and rituximab (2 %) [ 12 ] . Concomitant treatment with systemic antibiotics was always used in 2 % of the cases; frequently, in 10 %; rarely, in 54 %; or never, in 34 %.
Below, we will discuss the various topical and systemic treatment options based on their evidence and their therapeutic response:
Topical and intralesional treatment options
Apart from modern wound management, there may be an indication for topical class III and IV corticosteroids, especially in the early stages as well as in mild and localized disease. Small lesions in particular may benefi t from early topical therapy [ 13 ] . In case series, two out of fi ve patients were successfully treated with the topical calcineurin inhibitor tacrolimus (0.1 % ointment), especially those with mild and localized disease [ 14 ] , as well as four out of six patients using a gauze soaked in phenytoin 2 % solution in normal saline [ 15 ] . There have also been individual case reports describing the successful application of topical pimecrolimus 1 % cream [ 16, 17 ] . In the largest clinical trial of topical therapies for PG conducted by Lyon et al. in 2001 , eleven patients were treated with topical tacrolimus 0.3 % and compared with 17 patients who received topical clobetasol propionate 0.05 %. Topical tacrolimus was clearly superior to topical clobetasol propionate with regard to both complete healing (63.6 % vs. 29 %) as well as mean time to healing (5.1 vs. 6.5 weeks) and the clinical response of ulcerations > 2 cm [ 18 ] . In another case report, a woman, who had previously developed anaphylaxis following intravenous treatment with TNF α antibodies, showed complete resolution of PG lesions with topical application of infl iximab gel [ 19 ] . Intralesional administration of triamcinolone acetonide [ 20 ] and activated protein C [ 21 ] both resulted in a clinical response in two patients.
While topical treatment options, such as clobetasol propionate and tacrolimus, may be indicated in case of small individual lesions, very mild disease, or contraindications for systemic treatment, their response rate is signifi cantly lower than that of systemic agents (Table 1 ) , which is why the latter should be given preference. However, apart from mere wound treatment, topical immunosuppressive therapy may be additionally used in combination with systemic treatment. Indeed, the majority of German wound experts favor combination therapy [ 12 ] .
Surgical treatment options
The indication for surgical treatment of PG warrants great caution, as further tissue damage may trigger new lesions (pathergy phenomenon), and result in disease progression. Nevertheless, in case of suffi cient preceding immunosuppression, surgical therapy may be benefi cial, once the infl ammatory response has ceased and there is stable disease [ 22 ] . Healing of ulcerations and lesions can be facilitated with negative-pressure wound therapy, split-thickness (mesh graft) or full-thickness skin grafting (for example, Reverdin graft); in addition, there are fewer wound infections and immunosuppressive treatment is not required [ 23, 24 ] .
Systemic treatment options
The use of systemic therapy is indicated in patients with severe disease activity, multiple lesions, or failure of topical treatment, The most commonly used agents include corticosteroids at a dose of 0.5-2 mg/kg every day as well as steroidsparing immunosuppressants such as CsA, mycophenolate mofetil, azathioprine, dapsone, thalidomide, tacrolimus, as well as IVIG and biologics such as TNF α inhibitors [ 13, 25 ] . The best evidence-based study data is available for CsA, prednisolone, and infl iximab; the latter especially in patients with concomitant ulcerative colitis or Crohn's disease [ 7, 26 ] . However, response rates are highly variable, and only a subgroup of patients actually benefi ts from treatment. One possible reason for this might be misdiagnosis, given that -even in randomized trials -PG was usually diagnosed solely on clinical grounds, while histology failed to confi rm the diagnosis [ 27 ] . 
Corticosteroids
Corticosteroids are the most commonly used systemic agents for the treatment of PG, and are usually given at a dose of 0.5-2 mg/kg every day, depending on disease severity [ 2, 13, 25, 27 ] .
Cyclosporine A (CsA)
Cyclosporine A is usually given at a dose of 2-5 mg/kg daily, either in combination with corticosteroids as steroid-sparing co-medication or in case of failure to respond to corticosteroid treatment. In the only randomized blinded study hitherto published, which directly compared oral CsA vs. 
Other immunosuppressants
Other immunosuppressive agents successfully used and described in individual case reports include azathioprine (1. 
Biologics
Biologics hitherto used in the treatment of PG include the TNF α inhibitors infl iximab, adalimumab, etanercept, and certolizumab, the LFA-3-IgG fusion protein alefacept, the IL-12/23 antibody ustekinumab, the IL-1 receptor antagonist anakinra, the IL-1 β antibody canakinumab as well as IVIG [ 2, 12, 25, 26, 28, [30] [31] [32] [33] . TNF α antibodies: TNF α inhibitors have in particular been used in cases of PG associated with IBD such as ulcerative colitis or Crohn's disease. Since TNF α inhibitors, such as infl iximab and adalimumab, are approved for IBD, they are a suitable option for the treatment of both conditions, and are less affected by the problem of off-label use (Table 2 ) . Consequently, this is where one fi nds the largest patient collective, which tends to respond well to TNF α inhibitors [ 28, 34 ] . In the largest study to date (30 PG patients with and without IBD), 46 % (6/13) of individuals on infl iximab 5 mg/kg/d vs. 16 % (1/17) in the placebo group showed a response after 2 weeks; however, the observation period (2 weeks) was clearly too short. Various studies and case reports on infl iximab showed response and healing rates of up to 82 % and 48 %, respectively. For adalimumab, these fi gures were 100 % and 50 %; for etanercept, 92 % and 39 %, respectively [ 2, 6, 7, 26, 35 ] . While adalimumab has been successfully used as third-or fourth-line therapy in recalcitrant cases [ 36 ] , combination therapy consisting of prednisolone, oral steroid-sparing immunosuppressants (mycophenolate mofetil, CsA), and biologics have also been described in special cases [ 13, 26 ] . Given the risk of septic shock during treatment of PG with infl iximab [ 37 ] , antimicrobial prophylaxis (antibiotic, antifungal, and antiviral) may be indicated in severely immunosuppressed patients treated with TNF α inhibitors.
Intravenous immunoglobulins (IVIG)
In a larger case series, ten PG patients previously refractory to immunosuppressants were treated with IVIG 2 g/kg/d for three days every month (nine patients were continued on corticosteroids along with CsA or mycophenolate mofetil). Overall, seven patients showed a response, six of them even a sustained one [ 38 ] . In another case series, a complete response was reported in fi ve of seven and a partial response in two of seven PG patients; here, however, the dose administered was only 0.5 g/kg over the course of 2-3 days [ 39 ] .
New therapeutic approaches
New therapeutic approaches are the result of a better understanding of the etiopathogenesis. A subgroup of patients, who only insuffi ciently respond to conventional immunosuppressants, may respond to novel targeted therapies such as ustekinumab, anakinra, and the monoclonal IL-1 β antibody canakinumab [ 9, 30 ] , and possibly even to IL-17 antagonists [ 28, 32, 40, 41 ] . In a multicenter study that included fi ve patients with corticosteroid-refractory PG (dose 150 mg canakinumab SQ on day 1 and 14; three patients another 150-300 mg on day 56), three patients experienced complete resolution of PG; one patient at least showed a clinical response [ 9 ] .
Among the various systemic treatment options, evidence of therapeutic response -based on randomized clinical studies with case numbers of 80-100 patients -exists for only three agents (prednisolone, CsA, infl iximab). Prednisolone and prednisone are the only approved drugs for PG. TNF α 2 ) . These agents may therefore be considered second-line therapies. Because of their reasonable side effect profi le and the signifi cantly lower costs associated with them (compared to biologics), steroid-sparing agents -such as dapsone -may also be considered for long-term therapy. No matter the immunosuppressive therapy eventually chosen, the risk of superinfection of skin lesions with subsequent progression to sepsis has to be borne in mind.
Conclusion
Given the rarity of the disease and the lack of robust evidence provided by randomized double-blind studies, there is no uniform therapeutic standard, which consequently complicates treatment selection. A better understanding of the disease might result in the use of modern targeted therapies. Especially the novel therapeutic approaches using biologics urgently require further clinical studies with larger patient groups.
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